Scynexis (SCYX) Cash from Investing Activities Growth (1y) (2014 - 2026)
Scynexis (SCYX) Cash from Investing Activities Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -308.05% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -41.51% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -139.86% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 129.18% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 1.71% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -366.90% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -96.43% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Scynexis | 61.37 Mn | -53.33 Mn | - | -319.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -319.62% |
| Mar 31, 2026 | -104.22% |
| Dec 31, 2025 | -351.82% |
| Sep 30, 2025 | 539.72% |
| Jun 30, 2025 | 721.65% |
| Mar 31, 2025 | 128.09% |
| Dec 31, 2024 | -21.61% |
| Sep 30, 2024 | 107.37% |
| Jun 30, 2024 | 121.49% |
| Sep 30, 2023 | 3.79% |
| Sep 30, 2022 | -8,000.59% |
| Mar 31, 2022 | 95.50% |
| Sep 30, 2021 | -109.47% |
| Jun 30, 2021 | -100.48% |
| Mar 31, 2021 | 97.42% |
| Sep 30, 2020 | 948.22% |
| Jun 30, 2020 | 6.44% |
| Mar 31, 2020 | -217.66% |
| Dec 31, 2019 | 1,588.07% |
| Sep 30, 2019 | -102.82% |